Rose Do
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rose Do has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jing Wang
Acumen, LLC, 500 Airport Blvd. Suite 100, Burlingame, CA 94010, United States
3 shared publications - Mao Hu
Acumen, LLC, 500 Airport Blvd. Suite 100, Burlingame, CA 94010, United States
3 shared publications - Patricia C. Lloyd
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States
3 shared publications - Richard A. Forshee
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States
3 shared publications - Steven A. Anderson
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States
3 shared publications - Tainya C. Clarke
Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, 10903 New Hampshire Ave., Building 71, Silver Spring, MD 20993, United States
3 shared publications
Latest Publications
- Open Access
Evaluation of Guillain-Barré syndrome following Respiratory Syncytial Virus Vaccination among Medicare Beneficiaries 65 Years and Older
Importance: The United States Food and Drug Administration conducts routine post-market surveillance of approved vaccines to identify and characterize health outcomes risk associated with vaccination. Pre-licensure clinical trials of RSVPreF3+AS01 and RSVPreF vaccines identified a small number of Guillain-Barré syndrome cases, a serious acute demyelinating disease, following vaccination. Objective: To use Centers for Medicare & Medicaid Services Medicare Fee-for-Service administrative claims and Medicare Part D data to evaluate risk of Guillain-Barré syndrome following respiratory syncytial virus vaccination. Design, Settings, and Participants: We studied vaccines administered between May 3, 2023, when vaccines were first approved, through January 28, 2024. This self-controlled case series study design compared the incidence of Guillain-Barré syndrome during risk intervals of 1–42 days following vaccination to the incidence in subsequent control intervals (43–90 days) among Medicare beneficiaries, aged 65 years and older, enrolled in Fee-for-Service and Medicare Part D. Exposures: Receipt of a single dose of RSVPreF3+AS01 or RSVPreF vaccines. Outcomes: Guillain-Barré syndrome was identified using diagnosis code G61.0 in the primary diagnosis position on hospital inpatient claims; returned cases were confirmed via medical record review using Brighton Collaboration’s case definition. Results: We captured approximately 3.23 million Medicare beneficiaries that received respiratory syncytial virus vaccination during the study period. A total of 95 incident Guillain-Barré syndrome cases were observed following respiratory syncytial virus vaccination. In our chart-confirmed self-controlled case series analysis, we observed an increased incidence of Guillain-Barré syndrome following RSVPreF3+AS01 (IRR: 2.46, [95% CI: 1.19, 5.08]) with an attributable risk of 6.5 cases per 1 million doses. We observed an increased, yet not statistically significant, incidence of Guillain-Barré syndrome following RSVPreF (IRR: 2.02, [95% CI: 0.93, 4.40]) with an attributable risk of 9 cases per 1 million doses. Conclusion and Relevance: Findings from this self-controlled case series study suggest an increased risk of Guillain-Barré syndrome during 1-42 days following respiratory syncytial virus vaccination, with fewer than 10 excess Guillain-Barré syndrome cases per 1 million vaccine doses among Medicare beneficiaries 65 years and older. The U.S. Food and Drug Administration maintains that the substantial benefits of RSV vaccination outweigh these identified risks associated with vaccines. Key Points: Question: Is there an increased risk of developing Guillain-Barré syndrome (GBS) following vaccination with RSVPreF3+AS01 (AREXVY®) and RSVPreF (ABRYSVO®) among Medicare beneficiaries aged 65 years and older? Findings: In a self-controlled case series analysis of Medicare beneficiaries with medical record review, we estimated the incidence rate ratio (IRR) comparing GBS in pre-specified risk and control intervals following vaccination with RSVPreF3+AS01 (IRR: 2.46, 95%CI: 1.19-5.08) or RSVPreF (IRR: 2.02, 95%CI: 0.93-4.40). RSV vaccines were associated with fewer than 10 excess GBS cases per 1 million vaccine doses. Meaning: These findings suggest an increased risk of GBS following RSV vaccination.
Open AccessEvaluation of Guillain-Barré syndrome following Respiratory Syncytial Virus Vaccination among Medicare Beneficiaries 65 Years and Older
Importance: The United States Food and Drug Administration conducts routine post-market surveillance of approved vaccines to identify and characterize health outcomes risk associated with vaccination. Pre-licensure clinical trials of RSVPreF3+AS01 and RSVPreF vaccines identified a small number of Guillain-Barré syndrome cases, a serious acute demyelinating disease, following vaccination. Objective: To use Centers for Medicare & Medicaid Services Medicare Fee-for-Service administrative claims and Medicare Part D data to evaluate risk of Guillain-Barré syndrome following respiratory syncytial virus vaccination. Design, Settings, and Participants: We studied vaccines administered between May 3, 2023, when vaccines were first approved, through January 28, 2024. This self-controlled case series study design compared the incidence of Guillain-Barré syndrome during risk intervals of 1–42 days following vaccination to the incidence in subsequent control intervals (43–90 days) among Medicare beneficiaries, aged 65 years and older, enrolled in Fee-for-Service and Medicare Part D. Exposures: Receipt of a single dose of RSVPreF3+AS01 or RSVPreF vaccines. Outcomes: Guillain-Barré syndrome was identified using diagnosis code G61.0 in the primary diagnosis position on hospital inpatient claims; returned cases were confirmed via medical record review using Brighton Collaboration’s case definition. Results: We captured approximately 3.23 million Medicare beneficiaries that received respiratory syncytial virus vaccination during the study period. A total of 95 incident Guillain-Barré syndrome cases were observed following respiratory syncytial virus vaccination. In our chart-confirmed self-controlled case series analysis, we observed an increased incidence of Guillain-Barré syndrome following RSVPreF3+AS01 (IRR: 2.46, [95% CI: 1.19, 5.08]) with an attributable risk of 6.5 cases per 1 million doses. We observed an increased, yet not statistically significant, incidence of Guillain-Barré syndrome following RSVPreF (IRR: 2.02, [95% CI: 0.93, 4.40]) with an attributable risk of 9 cases per 1 million doses. Conclusion and Relevance: Findings from this self-controlled case series study suggest an increased risk of Guillain-Barré syndrome during 1-42 days following respiratory syncytial virus vaccination, with fewer than 10 excess Guillain-Barré syndrome cases per 1 million vaccine doses among Medicare beneficiaries 65 years and older. The U.S. Food and Drug Administration maintains that the substantial benefits of RSV vaccination outweigh these identified risks associated with vaccines. Key Points: Question: Is there an increased risk of developing Guillain-Barré syndrome (GBS) following vaccination with RSVPreF3+AS01 (AREXVY®) and RSVPreF (ABRYSVO®) among Medicare beneficiaries aged 65 years and older? Findings: In a self-controlled case series analysis of Medicare beneficiaries with medical record review, we estimated the incidence rate ratio (IRR) comparing GBS in pre-specified risk and control intervals following vaccination with RSVPreF3+AS01 (IRR: 2.46, 95%CI: 1.19-5.08) or RSVPreF (IRR: 2.02, 95%CI: 0.93-4.40). RSV vaccines were associated with fewer than 10 excess GBS cases per 1 million vaccine doses. Meaning: These findings suggest an increased risk of GBS following RSV vaccination.
- Open Access
Evaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S
Background Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevations in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluations of the potential associations. Methods We conducted self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged 65 years and older. Adjusted incidence rate ratio (IRRs) and 95% confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following booster doses for AMI, PE, ITP, Bell ‘s Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri). Results Among 3,360,981 individuals who received 6,388,542 primary series doses and 6,156,100 individuals with monovalent booster doses of either BNT162b2 or mRNA-1273, AE counts were: AMI (3,653 primary series, 16,042 booster), inpatient PE (2,470 primary, 5,085 booster), ITP (1,085 primary, 88 booster), DIC (254 primary), BP (3,268 booster), and Myo/Peri (1,295 booster). The IRR for inpatient PE cases following BNT162b2 primary series and booster was 1.19 (95% CI: 1.03 to 1.38) and 0.86 (95% CI: 0.78 to 0.95), respectively; and for mRNA-1273 primary series and booster, 1.15 (95% CI: 0.94 to 1.41) and 0.87 (95% CI: 0.79 to 0.96), respectively. The IRR for BP following BNT162b2 and mRNA-1273 booster was 1.17 (95% CI: 1.06 to 1.29) and 1.16 (95% CI: 1.05 to 1.29), respectively. Conclusion In these two studies of the U.S. elderly we did not find an increased risk for AMI, ITP, DIC, and Myo/Peri; the results were not consistent for PE; and there was a small elevated risk of BP after exposure to COVID-19 mRNA vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the elderly. HIGHLIGHTS There was no increased risk for four of six outcomes following COVID-19 monovalent mRNA vaccines. There was a small elevated risk of Bell ‘s Palsy after exposure to COVID-19 monovalent mRNA vaccines. Risk of pulmonary embolism was not consistent after exposure to COVID-19 monovalent mRNA vaccines.
Open AccessEvaluation of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Adults Aged 65 Years and Older: A Self-Controlled Study in the U.S
Background Our near-real-time safety monitoring of 16 adverse events (AEs) following COVID-19 mRNA vaccination identified potential elevations in risk for six AEs following primary series and monovalent booster dose administration. The crude association with AEs does not imply causality. Accordingly, we conducted robust evaluations of the potential associations. Methods We conducted self-controlled case series studies of COVID-19 mRNA vaccines (BNT162b2 and mRNA-1273) in U.S. Medicare beneficiaries aged 65 years and older. Adjusted incidence rate ratio (IRRs) and 95% confidence intervals (CIs) were estimated following primary series doses for acute myocardial infarction (AMI), pulmonary embolism (PE), immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC); and following booster doses for AMI, PE, ITP, Bell ‘s Palsy (BP) and Myocarditis/Pericarditis (Myo/Peri). Results Among 3,360,981 individuals who received 6,388,542 primary series doses and 6,156,100 individuals with monovalent booster doses of either BNT162b2 or mRNA-1273, AE counts were: AMI (3,653 primary series, 16,042 booster), inpatient PE (2,470 primary, 5,085 booster), ITP (1,085 primary, 88 booster), DIC (254 primary), BP (3,268 booster), and Myo/Peri (1,295 booster). The IRR for inpatient PE cases following BNT162b2 primary series and booster was 1.19 (95% CI: 1.03 to 1.38) and 0.86 (95% CI: 0.78 to 0.95), respectively; and for mRNA-1273 primary series and booster, 1.15 (95% CI: 0.94 to 1.41) and 0.87 (95% CI: 0.79 to 0.96), respectively. The IRR for BP following BNT162b2 and mRNA-1273 booster was 1.17 (95% CI: 1.06 to 1.29) and 1.16 (95% CI: 1.05 to 1.29), respectively. Conclusion In these two studies of the U.S. elderly we did not find an increased risk for AMI, ITP, DIC, and Myo/Peri; the results were not consistent for PE; and there was a small elevated risk of BP after exposure to COVID-19 mRNA vaccines. These results support the favorable safety profile of COVID-19 mRNA vaccines administered in the elderly. HIGHLIGHTS There was no increased risk for four of six outcomes following COVID-19 monovalent mRNA vaccines. There was a small elevated risk of Bell ‘s Palsy after exposure to COVID-19 monovalent mRNA vaccines. Risk of pulmonary embolism was not consistent after exposure to COVID-19 monovalent mRNA vaccines.
- 5 October 2021
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 104 (1) , 70-77
Development of a Knee Arthroplasty Episode-Based Cost Measure for Evaluating Cost in the Merit-Based Incentive Payment System
Background: Under the Merit-based Incentive Payment System (MIPS), the U.S. Centers for Medicare and Medicaid Services (CMS) evaluate clinicians who manage Medicare patients on the basis of cost and quality outcomes. CMS contractor Acumen, LLC, convened an expert panel to develop a knee arthroplasty episode-based cost measure (EBCM) for use in the MIPS. Methods: A Clinical Subcommittee of 28 clinician experts affiliated with 27 specialty societies provided guidance in developing the knee arthroplasty EBCM. The Clinical Subcommittee specified all aspects of the EBCM including triggering of the episode, services within the episode, risk adjustment, subgrouping, and exclusions. Services were counted only if the Clinical Subcommittee deemed them under the influence of the clinician assigned to the EBCM (selective service assignment; SSA). We assessed the reliability of the EBCM and compared it with an alternative population-based cost measure constructed without SSA. Results: We identified 249,301 knee arthroplasty episodes from June 1, 2016, to May 31, 2017, with 10,681 clinicians having at least 10 attributed episodes. The mean episode cost was $19,321 with a standard deviation of $1,816. SSA increased the reliability score from 0.71 to 0.81 relative to an alternative measure that counted all patient costs. SSA also led to reclassification of 41.8% of clinicians into different quintiles of performance. Conclusions: We found that the use of SSA in the creation of the EBCM substantially reduces random noise (i.e., unrelated medical procedures or costs) and offers a tool for assessing clinicians’ costs of management that is focused on care directly related to knee arthroplasty.
- 5 October 2021
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 104 (1) , 70-77
Development of a Knee Arthroplasty Episode-Based Cost Measure for Evaluating Cost in the Merit-Based Incentive Payment System
Background: Under the Merit-based Incentive Payment System (MIPS), the U.S. Centers for Medicare and Medicaid Services (CMS) evaluate clinicians who manage Medicare patients on the basis of cost and quality outcomes. CMS contractor Acumen, LLC, convened an expert panel to develop a knee arthroplasty episode-based cost measure (EBCM) for use in the MIPS. Methods: A Clinical Subcommittee of 28 clinician experts affiliated with 27 specialty societies provided guidance in developing the knee arthroplasty EBCM. The Clinical Subcommittee specified all aspects of the EBCM including triggering of the episode, services within the episode, risk adjustment, subgrouping, and exclusions. Services were counted only if the Clinical Subcommittee deemed them under the influence of the clinician assigned to the EBCM (selective service assignment; SSA). We assessed the reliability of the EBCM and compared it with an alternative population-based cost measure constructed without SSA. Results: We identified 249,301 knee arthroplasty episodes from June 1, 2016, to May 31, 2017, with 10,681 clinicians having at least 10 attributed episodes. The mean episode cost was $19,321 with a standard deviation of $1,816. SSA increased the reliability score from 0.71 to 0.81 relative to an alternative measure that counted all patient costs. SSA also led to reclassification of 41.8% of clinicians into different quintiles of performance. Conclusions: We found that the use of SSA in the creation of the EBCM substantially reduces random noise (i.e., unrelated medical procedures or costs) and offers a tool for assessing clinicians’ costs of management that is focused on care directly related to knee arthroplasty.